See more : Russel Metals Inc. (RUS.TO) Income Statement Analysis – Financial Results
Complete financial analysis of vTv Therapeutics Inc. (VTVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of vTv Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- As Commercial Industrial Company of Computers and Toys S.A. (ASCO.AT) Income Statement Analysis – Financial Results
- Faurecia S.E. (EO.MI) Income Statement Analysis – Financial Results
- Gran Tierra Energy Inc. (GTE.L) Income Statement Analysis – Financial Results
- ASOS Plc (ASC.L) Income Statement Analysis – Financial Results
- NanoLogix, Inc. (NNLX) Income Statement Analysis – Financial Results
vTv Therapeutics Inc. (VTVT)
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.02M | 4.01M | 6.41M | 2.76M | 12.43M | 291.00K | 634.00K | 519.00K | 1.55M | 976.00K |
| Cost of Revenue | 13.60M | 92.00K | 89.00K | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| Gross Profit | -13.60M | 1.93M | 3.92M | -4.60M | -12.36M | -10.60M | -39.35M | -45.11M | -29.07M | -17.18M | -24.46M |
| Gross Profit Ratio | 0.00% | 95.44% | 97.78% | -71.73% | -447.00% | -85.26% | -13,521.99% | -7,115.77% | -5,600.19% | -1,109.10% | -2,505.94% |
| Research & Development | 13.60M | 12.36M | 13.32M | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| General & Administrative | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Other Expenses | -13.60M | -2.67M | 4.06M | -270.00K | 828.00K | -592.00K | -190.00K | -22.00K | -2.97M | -1.13M | -534.00K |
| Operating Expenses | 11.91M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Cost & Expenses | 25.50M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Interest Income | 472.00K | 352.00K | 1.00K | 12.00K | 53.00K | 61.00K | 117.00K | 87.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.00K | 15.00K | 12.00K | 692.00K | 1.83M | 3.29M | 3.09M | 398.00K | 1.74M | 6.01M | 11.82M |
| Depreciation & Amortization | 90.00K | 92.00K | 89.00K | 94.00K | 39.00K | 218.00K | 197.00K | 265.00K | 501.00K | 864.00K | 1.09M |
| EBITDA | -25.41M | -24.77M | -17.52M | -12.02M | -19.97M | -20.14M | -50.56M | -54.69M | -38.87M | -29.23M | -35.30M |
| EBITDA Ratio | 0.00% | -1,231.81% | -439.55% | -188.81% | -723.99% | -163.70% | -17,441.58% | -8,667.98% | -7,349.13% | -1,882.44% | -3,614.86% |
| Operating Income | -25.50M | -22.54M | -21.66M | -11.85M | -20.89M | -19.82M | -50.68M | -55.02M | -38.14M | -28.90M | -35.83M |
| Operating Income Ratio | 0.00% | -1,116.95% | -540.87% | -184.78% | -755.86% | -159.43% | -17,416.49% | -8,678.23% | -7,349.13% | -1,865.53% | -3,671.41% |
| Total Other Income/Expenses | -464.00K | -2.33M | 4.05M | -950.00K | -946.00K | -3.82M | -3.17M | -333.00K | -2.97M | -7.20M | -12.37M |
| Income Before Tax | -25.97M | -24.87M | -17.62M | -12.80M | -21.84M | -23.65M | -53.85M | -55.35M | -41.11M | -36.10M | -48.20M |
| Income Before Tax Ratio | 0.00% | -1,232.56% | -439.85% | -199.59% | -790.09% | -190.16% | -18,504.12% | -8,730.76% | -7,920.42% | -2,330.60% | -4,938.83% |
| Income Tax Expense | 0.00 | 200.00K | 115.00K | -3.98M | 100.00K | 200.00K | 800.00K | -39.00M | -14.11M | 4.88M | 11.29M |
| Net Income | -20.25M | -25.07M | -17.73M | -8.83M | -21.94M | -7.91M | -16.14M | -16.35M | -27.50M | -36.10M | -48.20M |
| Net Income Ratio | 0.00% | -1,242.47% | -442.72% | -137.62% | -793.70% | -63.62% | -5,547.77% | -2,579.18% | -5,298.27% | -2,330.60% | -4,938.83% |
| EPS | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| EPS Diluted | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| Weighted Avg Shares Out | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
| Weighted Avg Shares Out (Dil) | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Source: https://incomestatements.info
Category: Stock Reports